Interferon-modulated vaccines against HIV
$81,547DP2FY2023DANIH
Northwestern University At Chicago, Evanston IL
Investigators
Linked publications & trials
Paper 39432667Paper 39186606Paper 39007643Paper 38861331Paper 38822334Paper 38496467Paper 38106001Paper 37313412Paper 37090595Paper 36992700Paper 36857186Paper 36219482Paper 35958615Paper 35794898Paper 34943952Paper 34761549Paper 34648369Paper 34623973Paper 34450033Paper 33907732Paper 33821275Paper 32820330
Abstract
Project Summary The main goal of the parent grant is to develop interferon-modulated vaccines against HIV. The proposed research will follow up on the same unifying concept of our parent DP2 grant, but in addition, it will consider the effect of boosting with a heterologous vaccine. Bakare has observed that boosting with a heterologous vaccine regimen enhances the efficacy of vaccines (manuscript in preparation). The preliminary data shown below is with SARS-CoV-2 vaccines, but it demonstrates a potentially novel and universal strategy to improve viral vaccines against HIV and other infectious agents that affect PWID. Improving vaccine efficacy is also critical to improve the lives of PWID.
View original record on NIH RePORTER →